FDA批准-话题@MedSci

#FDA批准#

870篇内容 | 8139人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1839666, encodeId=c7bc1839666dd, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准NKMax America的NK细胞疗法SNK01用于难治性癌症患者的1期临床试验, objectType=article, longId=161784, objectId=176a161e8475, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=176a161e8475, replyNumber=0, likeNumber=63, createdTime=2020-01-26, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=176a161e8475, moduleTitle=FDA批准NKMax America的NK细胞疗法SNK01用于难治性癌症患者的1期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=176a161e8475)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839673, encodeId=d1a918396e338, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准将赛妥珠单抗用于治疗非放射性轴性脊柱关节炎（nr-axSpA）, objectType=article, longId=163432, objectId=dd7516343269, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dd7516343269, replyNumber=0, likeNumber=69, createdTime=2019-09-09, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dd7516343269, moduleTitle=FDA批准将赛妥珠单抗用于治疗非放射性轴性脊柱关节炎（nr-axSpA）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dd7516343269)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839675, encodeId=6d7e18396e5d9, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=男性乳腺癌：美国FDA批准IBRANCE（palbociclib）用于治疗HR+/HER2-的男性乳腺癌患者, objectType=article, longId=163717, objectId=ffde163e1796, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ffde163e1796, replyNumber=0, likeNumber=52, createdTime=2019-11-06, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ffde163e1796, moduleTitle=男性乳腺癌：美国FDA批准IBRANCE（palbociclib）用于治疗HR+/HER2-的男性乳腺癌患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ffde163e1796)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839609, encodeId=67511839609cc, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准PERSERIS（利培酮）延长释放悬浮液治疗成人精神分裂症, objectType=article, longId=145540, objectId=3f6e145540e6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3f6e145540e6, replyNumber=0, likeNumber=66, createdTime=2018-09-12, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3f6e145540e6, moduleTitle=FDA批准PERSERIS（利培酮）延长释放悬浮液治疗成人精神分裂症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3f6e145540e6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839692, encodeId=633e183969290, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准诺华的Piqray用于治疗PIK3CA突变的晚期或转移性乳腺癌, objectType=article, longId=167492, objectId=4e2216e4929e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4e2216e4929e, replyNumber=0, likeNumber=54, createdTime=2019-06-13, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4e2216e4929e, moduleTitle=FDA批准诺华的Piqray用于治疗PIK3CA突变的晚期或转移性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4e2216e4929e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839655, encodeId=3375183965587, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=诺和诺德的长效化凝血因子VIII（ESPEROCT）获FDA批准治疗A型血友病, objectType=article, longId=160654, objectId=f5c7160654df, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f5c7160654df, replyNumber=0, likeNumber=0, createdTime=2019-10-14, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f5c7160654df, moduleTitle=诺和诺德的长效化凝血因子VIII（ESPEROCT）获FDA批准治疗A型血友病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f5c7160654df)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839676, encodeId=36d818396e673, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准过饱和氧治疗系统治疗“寡妇病变”, objectType=article, longId=163925, objectId=4d881639253d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4d881639253d, replyNumber=0, likeNumber=54, createdTime=2019-05-31, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4d881639253d, moduleTitle=FDA批准过饱和氧治疗系统治疗“寡妇病变”, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4d881639253d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839631, encodeId=e3c81839631cd, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准罗氏A型血友病重磅药Hemlibra获批, objectType=article, longId=150489, objectId=aa11150489d3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aa11150489d3, replyNumber=0, likeNumber=42, createdTime=2019-02-01, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aa11150489d3, moduleTitle=FDA批准罗氏A型血友病重磅药Hemlibra获批, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aa11150489d3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839651, encodeId=67d0183965194, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准：AbbVie与强生公司的伊布替尼作为CLL一线治疗的第一个非化疗联合方案, objectType=article, longId=159161, objectId=a1f815916100, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a1f815916100, replyNumber=0, likeNumber=57, createdTime=2019-05-29, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a1f815916100, moduleTitle=FDA批准：AbbVie与强生公司的伊布替尼作为CLL一线治疗的第一个非化疗联合方案, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a1f815916100)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839623, encodeId=f91318396237c, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准Verastem公司PI3K 抑制剂Copiktra用于治疗血癌, objectType=article, longId=149621, objectId=d13714962110, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d13714962110, replyNumber=0, likeNumber=77, createdTime=2019-02-09, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d13714962110, moduleTitle=FDA批准Verastem公司PI3K 抑制剂Copiktra用于治疗血癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d13714962110)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839677, encodeId=2ce818396e7e4, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=葛兰素史克的双药片剂Dovato治疗艾滋病获FDA批准上市, objectType=article, longId=163973, objectId=7dc91639e359, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7dc91639e359, replyNumber=0, likeNumber=64, createdTime=2019-07-29, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7dc91639e359, moduleTitle=葛兰素史克的双药片剂Dovato治疗艾滋病获FDA批准上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7dc91639e359)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839642, encodeId=9d8118396429c, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=2018年FDA批准的临床试验进展的新药汇总, objectType=article, longId=156201, objectId=067f1562012f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=067f1562012f, replyNumber=0, likeNumber=79, createdTime=2019-11-11, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=067f1562012f, moduleTitle=2018年FDA批准的临床试验进展的新药汇总, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=067f1562012f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839632, encodeId=993c1839632ad, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准反义RNA疗法上市治疗难治神经疾病, objectType=article, longId=150490, objectId=74b7150490cd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=74b7150490cd, replyNumber=0, likeNumber=71, createdTime=2019-01-28, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=74b7150490cd, moduleTitle=FDA批准反义RNA疗法上市治疗难治神经疾病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=74b7150490cd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839648, encodeId=7941183964878, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准安进/优时比的抗骨质疏松新药Evenity上市, objectType=article, longId=159029, objectId=5e45159029d8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5e45159029d8, replyNumber=0, likeNumber=0, createdTime=2019-06-12, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5e45159029d8, moduleTitle=FDA批准安进/优时比的抗骨质疏松新药Evenity上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5e45159029d8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839661, encodeId=c9c4183966181, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准GLOPERBA（秋水仙碱）用于预防成人痛风, objectType=article, longId=161340, objectId=cbe216134065, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cbe216134065, replyNumber=0, likeNumber=68, createdTime=2019-06-20, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cbe216134065, moduleTitle=FDA批准GLOPERBA（秋水仙碱）用于预防成人痛风, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cbe216134065)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839627, encodeId=0d0e183962e12, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=美国FDA批准VIZIMPRO用于EGFR突变的转移性非小细胞肺癌的一线治疗, objectType=article, longId=149975, objectId=90091499e58a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=90091499e58a, replyNumber=0, likeNumber=64, createdTime=2019-07-16, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=90091499e58a, moduleTitle=美国FDA批准VIZIMPRO用于EGFR突变的转移性非小细胞肺癌的一线治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=90091499e58a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839652, encodeId=67ec18396525d, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=Allogene与Servier宣布FDA批准ALLO-501的IND, objectType=article, longId=159163, objectId=daa71591634d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=daa71591634d, replyNumber=0, likeNumber=55, createdTime=2019-09-14, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=daa71591634d, moduleTitle=Allogene与Servier宣布FDA批准ALLO-501的IND, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=daa71591634d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839602, encodeId=06bc1839602f2, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准Dermira的Qbrexza治疗原发性腋窝多汗症, objectType=article, longId=142036, objectId=90ff14203604, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=90ff14203604, replyNumber=0, likeNumber=68, createdTime=2018-12-25, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=90ff14203604, moduleTitle=FDA批准Dermira的Qbrexza治疗原发性腋窝多汗症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=90ff14203604)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839669, encodeId=05351839669eb, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=罗氏的PD-L1单抗Tecentriq 治疗三阴性乳腺癌即将获得FDA批准, objectType=article, longId=162148, objectId=423a1621482c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=423a1621482c, replyNumber=0, likeNumber=70, createdTime=2019-12-28, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=423a1621482c, moduleTitle=罗氏的PD-L1单抗Tecentriq 治疗三阴性乳腺癌即将获得FDA批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=423a1621482c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839620, encodeId=882e183962096, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=默沙东HIV新药Delstrigo和Pifeltro获得FDA批准上市, objectType=article, longId=147983, objectId=fcca14e983e4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fcca14e983e4, replyNumber=0, likeNumber=96, createdTime=2018-09-25, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fcca14e983e4, moduleTitle=默沙东HIV新药Delstrigo和Pifeltro获得FDA批准上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fcca14e983e4)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

FDA批准

2020-05-29发表于威斯康星

智者为医08 (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准NKMax America的NK细胞疗法SNK01用于难治性癌症患者的1期临床试验

2020-01-26

智者为医08 (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准将赛妥珠单抗用于治疗非放射性轴性脊柱关节炎（nr-axSpA）

2019-09-09

智者为医08 (审核中...)

前往app查看评论内容

#FDA批准#

男性乳腺癌：美国FDA批准IBRANCE（palbociclib）用于治疗HR+/HER2-的男性乳腺癌患者

2019-11-06

智者为医08 (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准PERSERIS（利培酮）延长释放悬浮液治疗成人精神分裂症

2018-09-12

智者为医08 (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准诺华的Piqray用于治疗PIK3CA突变的晚期或转移性乳腺癌

2019-06-13

智者为医08 (审核中...)

前往app查看评论内容

#FDA批准#

诺和诺德的长效化凝血因子VIII（ESPEROCT）获FDA批准治疗A型血友病

2019-10-14

智者为医08 (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准过饱和氧治疗系统治疗“寡妇病变”

2019-05-31

智者为医08 (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准罗氏A型血友病重磅药Hemlibra获批

2019-02-01

智者为医08 (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准：AbbVie与强生公司的伊布替尼作为CLL一线治疗的第一个非化疗联合方案

2019-05-29

智者为医08 (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准Verastem公司PI3K 抑制剂Copiktra用于治疗血癌

2019-02-09

智者为医08 (审核中...)

前往app查看评论内容

#FDA批准#

葛兰素史克的双药片剂Dovato治疗艾滋病获FDA批准上市

2019-07-29

智者为医08 (审核中...)

前往app查看评论内容

#FDA批准#

2018年FDA批准的临床试验进展的新药汇总

2019-11-11

智者为医08 (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准反义RNA疗法上市治疗难治神经疾病

2019-01-28

智者为医08 (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准安进/优时比的抗骨质疏松新药Evenity上市

2019-06-12

智者为医08 (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准GLOPERBA（秋水仙碱）用于预防成人痛风

2019-06-20

智者为医08 (审核中...)

前往app查看评论内容

#FDA批准#

美国FDA批准VIZIMPRO用于EGFR突变的转移性非小细胞肺癌的一线治疗

2019-07-16

智者为医08 (审核中...)

前往app查看评论内容

#FDA批准#

Allogene与Servier宣布FDA批准ALLO-501的IND

2019-09-14

智者为医08 (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准Dermira的Qbrexza治疗原发性腋窝多汗症

2018-12-25

智者为医08 (审核中...)

前往app查看评论内容

#FDA批准#

罗氏的PD-L1单抗Tecentriq 治疗三阴性乳腺癌即将获得FDA批准

2019-12-28

智者为医08 (审核中...)

前往app查看评论内容

#FDA批准#

默沙东HIV新药Delstrigo和Pifeltro获得FDA批准上市

2018-09-25

科室
- - 订阅+
  - 更多科室
工具
服务